Two rising biotech stocks. One clear long-term winner.
News & Analysis: Galapagos
GLPG earnings call for the period ending March 31, 2019.
Galapagos' experimental rheumatoid arthritis drug hit the mark in two late-stage studies last month.
Find out which of these stocks fared the best as the quarter came to a close.
The biotech reported nothing but good news from multiple clinical trials of its promising immunology drug.
These three healthcare gems have the full attention of our team of experts.
Clinical trial readouts expected before the end of March will put shares of these drugmakers on the move.
These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.
Which stock wins in a battle between these two biotechs?
It's beginning to look like AbbVie made a big mistake.